Core Viewpoint - Yongsheng Medical (01612) experienced a stock price increase of over 9% following a profit alert, with shares trading at HKD 0.94 and a transaction volume of HKD 5.3888 million [1] Financial Performance - The company anticipates an unaudited consolidated profit attributable to shareholders of no less than HKD 100 million for the fiscal year ending December 31, 2025 [1] - For the fiscal year ending December 31, 2024, the audited profit attributable to shareholders is expected to be approximately HKD 69.2 million [1] Business Drivers - The significant increase in revenue is attributed to strengthened relationships with a major customer in the imaging disposable products segment and the expansion of business scale [1] - The company has achieved better economies of scale by enhancing capacity utilization and operational efficiency, leading to improved gross margins [1]

市场监管总局网站，为纵深推进全国统一大市场建设，推动 长三角市场监管一体化发展，近日，市场 监管总局批复同意上海市、江苏省、浙江省、安徽省市场监管局在长三角地区开展 医疗器械广告跨区 域审查试点工作。试点工作聚焦医疗器械广告审查中的堵点问题，通过创新审批模式，对符合条件的医 疗器械广告审查申请，在长三角地区实行"一次申请、一地审查、一号核发"，从"小切口"入手，通过务 实举措，切实降低广告申请人办事成本，持续优化营商环境，提高服务企业效能，为改革完善广告审查 管理制度探索积累可复制、可推广的经验。 ...

一是强化顶层设计，培育支柱产业。将具身智能、脑机接口等未来产业，特别是面向民生服务的先进智 能装备和医疗器械等相关产业，摆在更加突出的战略位置，统筹推进全产业链布局。完善基础研究、技 术创新、产品开发到成果转化、场景应用、标准制定的政策支撑体系，推动"实验室技术"加速迈向"规 模化应用"。 二是聚焦核心技术，突破发展瓶颈。集中力量攻克"具身"感知与控制、"大脑"解码与决策、"机器人"本 体结构协同等关键技术难点，提升具身智能、脑机接口及机器人等技术的深度融合与生物智能水平。引 入世界人形机器人运动会、脑机接口开发者大会等，构建全球性专业交流平台，通过"以赛促研"模式， 推动技术快速迭代与产业生态构建。 三是开放多元场景，深化人机协同。由政府引导，在医疗、康养、教育、应急、民政、消费等领域，打 造规模化应用"试验田"，打通技术快速转化路径，破解"用不起"的推广难题，创造人机共融的新工作模 式。 采写：南都N视频记者叶孜文 赵青 杨伽 出品：南都政务新闻部 具身智能、脑机接口等未来科技，正快速应用于医疗、康养、教育等领域，生动地诠释了科技向善的力 量。前沿技术的蓬勃发展，不仅是科技的突破，更蕴含着深刻的社会变革意 ...

Group 1 - On January 27, brokerages set target prices for listed companies with notable increases for Changyuan Donggu, Hongyuan Green Energy, and Haotaitai, with target price increases of 50.61%, 42.37%, and 30.60% respectively, belonging to the automotive parts, photovoltaic equipment, and home goods industries [2][3] - A total of 29 listed companies received brokerage recommendations on January 27, with Tonghua Dongbao, Zhibang Home, and Yanjing Beer receiving one recommendation each [3] Group 2 - On January 27, one company had its rating upgraded, with Xinda Securities raising Xueda Education's rating from "Hold" to "Buy" [4][5] - Five companies received initial coverage on January 27, including Taihe New Materials with an "Accumulate" rating from Northeast Securities, Kelike with an "Outperform" rating from Guosen Securities, Tianyi Medical with a "Buy" rating from Xinda Securities, Xinhenghui with an "Accumulate" rating from Zhongyou Securities, and Tuojing Technology with a "Buy" rating from Donghai Securities [6]

Core Viewpoint - The company, Aidi Te (301580.SZ), is optimistic about its 3D printing business, which is expected to become a new core performance driver with significant advantages [1] Group 1: 3D Printing Business Development - The company's 3D printing business is progressing well and is anticipated to be a new core performance engine [1] - The EZprint-P1 printer has a high-speed printing advantage, capable of completing a half-arch bridge print in 20 minutes, significantly enhancing production efficiency in the industry [1] - The printing materials used have a solid content of 53% and have received FDA certification, with domestic and EU certifications expected to be finalized soon [1] Group 2: Market Potential and Applications - The company believes the dental 3D printing market has vast development and growth potential [1] - The maturity of 3D printing products and technologies is continuously improving, with applications expanding into various fields such as implants and orthodontics [1] - Relevant clinical solutions have completed market validation, supporting the company's strategic direction [1] Group 3: Competitive Advantage - The company leverages its full-chain layout advantages in materials, equipment, and solutions to deepen its focus on the 3D printing business [1]

证券之星消息，截至2026年1月27日收盘，大博医疗(002901)报收于51.9元，上涨7.45%，换手率 2.51%，成交量7.24万手，成交额3.71亿元。 近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： 大博医疗2025年三季报显示，前三季度公司主营收入18.76亿元，同比上升22.69%；归母净利润4.25亿 元，同比上升77.03%；扣非净利润3.46亿元，同比上升63.99%；其中2025年第三季度，公司单季度主营 收入6.66亿元，同比上升17.82%；单季度归母净利润1.8亿元，同比上升77.49%；单季度扣非净利润1.23 亿元，同比上升38.44%；负债率24.53%，投资收益580.87万元，财务费用-2387.47万元，毛利率 71.23%。大博医疗（002901）主营业务：医用高值耗材的生产、研发与销售。 1月27日的资金流向数据方面，主力资金净流入1299.83万元，占总成交额3.51%，游资资金净流出 987.92万元，占总成交额2.67%，散户资金净流出311.91万元，占总成交额0.84%。 该股最近90天内共有1家机构给出评级，买入评级1家。 近5日资金流 ...

格隆汇1月28日丨迈克生物(300463.SZ)在投资者互动平台表示，对于近期印度尼帕病毒，公司目前暂无 已获证的尼帕病毒检测产品。公司将根据产品战略规划，从临床需求紧迫性、技术实现可行性、注册程 序合规性等多个维度进行合理评估，审慎决策，同时严格履行信息披露义务。请您关注官方信息披露渠 道，谨慎投资，注意风险。 ...

春立医疗融资融券信息显示，融资方面，当日融资买入740.78万元，融资偿还656.02万元，融资净买入 84.76万元。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量1.24万股，融券余额31.99万元。融资 融券余额4090.05万元。 证券之星消息，截至2026年1月27日收盘，春立医疗(688236)报收于25.8元，下跌3.04%，换手率 0.87%，成交量2.5万手，成交额6458.86万元。 1月27日的资金流向数据方面，主力资金净流出13.76万元，占总成交额0.21%，游资资金净流入263.09 万元，占总成交额4.07%，散户资金净流出249.34万元，占总成交额3.86%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451. ...

Core Insights - 2025 marks a turning point for the global healthcare investment landscape, with a slight increase in financing events and amounts, indicating a recovery from previous downturns [2][6][10] Financing Trends - In 2025, the global healthcare industry saw a total of 2,353 financing events, accumulating $60.4 billion, representing a 4% increase in total financing compared to 2024 [8][10] - The number of financing events increased by approximately 3% from 2024, signaling a gradual recovery in the primary market [6][10] - The number of financing events exceeding $100 million has risen for three consecutive years, reflecting a positive recovery trend [3][12] Sector Analysis - The integration of artificial intelligence (AI) into various subfields has sparked a new wave of healthcare infrastructure investment, making it the most watched sector in 2025 [4][19] - In China, the innovative drug sector (NewCo) has shown potential, leading the financing rankings, with 2026 expected to be a critical year for evaluating its innovation [4][26] - Financing trends indicate a clear differentiation based on technology maturity, with mature sectors showing moderate amounts and events, while emerging sectors have fewer events but higher amounts [4][19] Quarterly Insights - Financing activities in the healthcare sector tend to concentrate in specific quarters, particularly in Q1 and Q3, with significant growth observed in H2 of 2025 compared to H2 of 2024, showing a recovery momentum [8][10] Investment Institutions - Nearly 130 institutions made five or more investments in 2025, a nearly 50% increase year-on-year, indicating a shift towards concentrated capital allocation among top-tier institutions [1][36] - Qiming Venture Partners led with 37 investments, followed by General Catalyst and OrbiMed, highlighting a trend of increased activity among prominent investors [36][39] Popular Investment Areas - The financing landscape in 2025 was dominated by sectors such as biopharmaceuticals, medical devices, and digital health, with significant increases in investment amounts for medical devices and digital health [15][19] - The top financing events included companies like Shields Health Solutions and BVI Medical, showcasing a diverse range of healthcare innovations attracting substantial capital [21][30] Domestic Market Insights - In China, the healthcare sector experienced a 32% increase in total financing compared to 2024, with 861 financing transactions totaling approximately $9.6 billion [10][24] - The domestic market's recovery is characterized by a significant increase in financing amounts, particularly in the medical device sector, which saw a 61% increase despite a slight decrease in transaction numbers [10][24] Conclusion - The healthcare investment landscape in 2025 reflects a complex interplay of recovery, sectoral shifts, and the emergence of AI as a foundational technology, with significant implications for future investment strategies [40]

Market Strategy - The market is experiencing a volume contraction while showing signs of recovery, with the semiconductor chip industry chain strengthening [5][8] - The overall A-share market index increased by 0.14%, with the Shanghai Composite Index rising by 0.18% and the Sci-Tech 50 Index leading with a 1.51% increase [8][9] - The semiconductor chip industry is supported by increased capital expenditure from TSMC, rising AI demand, and a strengthened domestic substitution logic due to trade uncertainties [10] Economic Insights - In 2025, the total profit of industrial enterprises above designated size in China is projected to reach CNY 73,982 billion, reflecting a year-on-year growth of 0.6% [18][19] - The People's Bank of China conducted a reverse repurchase operation of CNY 4,020 billion at an interest rate of 1.40% [20][21] - By the end of 2025, the entrusted investment scale of the basic pension insurance fund is expected to exceed CNY 2.98 trillion [23][24] Industry Dynamics - The EU has introduced policies to promote the recycling of regenerated plastics, requiring member states to ensure that 30% of materials in specific beverage bottles are made from recycled plastics by 2030 [27][28] - In 2025, China's shipment of cathode materials is expected to reach 4.987 million tons, with a total output value of CNY 274.39 billion, marking a year-on-year growth of 30.9% [29][30] - A coalition of multiple countries has signed the Hamburg Declaration to deliver 100GW of offshore wind power through large-scale joint projects [31][32] Company Tracking - China Merchants Securities (600999.SH) anticipates a 2025 net profit growth of 18.43%, with total revenue expected to reach CNY 24.9 billion [37][38] - Zhongsheng Pharmaceutical (002317.SZ) forecasts a net profit of CNY 260-310 million in 2025, representing a year-on-year increase of 186.91% to 203.62% [40][41] - Leksin Medical (300562.SZ) expects a net profit growth of 32.00% to 38.52% in 2025, with projected profits between CNY 81 million and 85 million [42][43] - Dongfang Securities (600958.SH) projects a 67.8% increase in net profit for 2025, with total revenue expected to reach CNY 15.34 billion [44][45] - Weijie Chuangxin (688153.SH) anticipates a net profit of CNY 45 million in 2025, marking a turnaround from losses [46][48] - Xiamen Tungsten (688778.SH) expects a net profit of approximately CNY 755 million in 2025, reflecting a growth of 41.83% [49][50]